FDA Accepts Sandoz Regulatory Submission For A Proposed Biosimilar Etanercept

October 24, 2015by prometheusip0

Sandoz, a Novartis company and the global leader in biosimilars, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel® (etanercept) – a tumor necrosis factor alpha (TNF-alpha) inhibitor.

prometheusip

prometheusip

Prometheus IP is a leading intellectual property service enterprise offering competent and economic Intellectual Property Rights (IPR) solutions which include Patents, Designs, Copyrights and Trademarks.

Prometheus IPHeadquarters
Prometheus Patent Services Pvt Ltd.
Plot No:34B, Sai Dwaraka Sinman,
Huda Heights, Near Lotuspond, MLA Colony
Road No.12, Banjara Hills,Hyderabad-500034
Telangana, India.
Our locationsWhere to find us?
https://prometheusip.com/wp-content/uploads/2020/01/footer-map.png
Get in touchPrometheus IP Social
Prometheus IPHeadquarters
Prometheus Patent Services Pvt Ltd.
Plot No:34B, Sai Dwaraka Sinman,
Huda Heights, Near Lotuspond, MLA Colony
Road No.12, Banjara Hills,Hyderabad-500034
Telangana, India.
Our locationsWhere to find us?
https://prometheusip.com/wp-content/uploads/2020/01/footer-map.png
Get in touchPrometheus IP Social

Copyright Prometheus IP. All rights reserved.

Copyright Prometheus IP. All rights reserved.